
Opinion|Videos|January 22, 2025
Long-Term Safety of Second-Line Therapies for PBC
Panelists discuss how long-term safety monitoring for second-line primary biliary cholangitis (PBC) therapies requires systematic assessment of liver function, lipid profiles, and potential drug-specific adverse effects while emerging 5-year safety data for seladelpar continues to demonstrate a favorable risk profile compared with other treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the potential risks of long-term therapy with seladelpar, elafibranor, and obeticholic acid, and how can clinicians monitor for and mitigate these risks?
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
- Discuss the 5-year safety data for seladelpar presented at AASLD 2024.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate
4
Incidence of VAIs in Patients With Chronic Kidney Disease on Dialysis Relatively Low
5













































































































































































































